A Randomized Controlled Trial to Assess the Impact of Live and Recorded Music-Based Interventions on Pre-operative Stress, Mood, Pain and Biomarkers, in Neurosurgical Patients (Music-STAR Trial)
Not Applicable
Recruiting
- Conditions
- PainStress
- Interventions
- Other: Steinway Spirio M recording/player piano
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 132
- Registration Number
- NCT06536504
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Opiophobia in Postsurgical Adults With Cancer
Active, not recruiting
- Conditions
- Opiophobia
- Interventions
- Other: 13-item Barriers Questionnaire (BQ-13)Other: Four-item Medication Adherence QuestionnaireOther: 14-item Hospital Anxiety and Depression Scale (HADS)
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06536283
- Locations
- 🇺🇸
The Univerisity of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Impact of Perioperative Anesthetic Management on Renal Cancer Progression.
Withdrawn
- Conditions
- Renal CancerPerioperative Anesthetic
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT06536244
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
AIM4 AI and Mechanistic Modeling in Molecular Medicine
Withdrawn
- Conditions
- Molecular Medicine
- Interventions
- Device: AI and mechanic modeling
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT06535828
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06522386
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
Phase 2
Withdrawn
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 168
- Registration Number
- NCT06522360
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT06522373
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
Recruiting
- Conditions
- Thyroid Cancer
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 459
- Registration Number
- NCT06507878
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
Phase 2
Not yet recruiting
- Conditions
- LymphedemaFibrosis
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 295
- Registration Number
- NCT06494111
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating with Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
Phase 1
Not yet recruiting
- Conditions
- Refractory Acute LeukemiaRelapsed Acute Leukemia
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06474663
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath